It may not have been pretty, but Regulus Therapeutics ($RGLS) raised close to $81 million from its recent IPO and some related transactions. And the company did it with a big assist from some major league partners in the biopharma industry. Report
| Tuesday, January 27 | 2 p.m. ET / 11 a.m. PT | Sponsored by: Veeva
As the life sciences industry evolves, commercial leaders are demanding more innovative and effective customer engagement, but traditional processes limited by legacy technology are holding them back. There is a better way that puts control back in the hands of commercial leaders and eliminates the barriers to coordinated customer engagement. Reserve Your Spot Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!